Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

[1]  L. Kappos,et al.  Long-term effects of fingolimod in multiple sclerosis , 2015, Neurology.

[2]  S. Amor,et al.  The sphingosine 1‐phosphate receptor agonist FTY720 is neuroprotective after cuprizone‐induced CNS demyelination , 2015, British journal of pharmacology.

[3]  J. Newcombe,et al.  Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide , 2014, Annals of neurology.

[4]  M. Freedman,et al.  First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. , 2014, Multiple sclerosis and related disorders.

[5]  Jeffrey A. Cohen,et al.  Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. , 2014, Multiple sclerosis and related disorders.

[6]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[7]  C. Pozzilli,et al.  Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial , 2014, BMC Neurology.

[8]  L. Kappos,et al.  Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy , 2014, Multiple sclerosis.

[9]  L. Kappos,et al.  Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study , 2013, Journal of Neurology.

[10]  R. Jager,et al.  Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. , 2013, Ophthalmology.

[11]  Jeffrey A. Cohen,et al.  Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS , 2013, Journal of Neurology.

[12]  Volker Brinkmann,et al.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.

[13]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[14]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[15]  H. Rosen,et al.  Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules , 2009, Nature Reviews Drug Discovery.

[16]  L. Kappos,et al.  FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis , 2008, Neurology.

[17]  V. Brinkmann.  Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.

[18]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[19]  G. Francis,et al.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.